>

Discovery

Integrated Discovery Platform
From Concept to IND

Monoclonal Antibody Discovery

More than 100 monoclonal antibodies (mAbs) have been approved in clinics for the treatment of cancer, autoimmune disorders, and inflammatory and infectious diseases. MAbs are also important building blocks for the design and construction of bispecific, multispecific and biparatopic antibodies, antibody drug conjugates (ADCs) and CAR (chimeric antigen receptor) T-cell therapeutics. WuXi Biologics has extensive experience in the generation and preclinical candidate lead (PCC) discovery of mAbs from human, mouse, rat, camelid and rabbit covering traditional and heavy-chain-only mAbs. WuXi Biologics has established multiple core technology platforms including hybridoma, phage display, and single B cell screening approaches for mAb discovery.

Hybridoma
Phage Display
Single B Cell Screening

Hybridoma

WuXi Biologics provides antibody generation through traditional hybridoma approaches using our WuXiHybrid™ advanced hybridoma-monoclonal antibody technology platform. We also offer multiple approaches for generating fully human antibodies using transgenic animals from either Ligand’s OmniAb® or Alloy Therapeutics’ ATX-Gx™ platforms. WuXi Biologics has successfully delivered 200+ therapeutic antibody discovery projects via our hybridoma platform. In addition, our team of experts have extensive experience with GPCR (G Protein-Coupled Receptor) & other difficult targets.

Key Features:

AAALAC accredited facilities
Transgenic mice/rats for fully human antibody generation
Multiple immunization strategies (DNA, peptide, protein, cell or combinations thereof) to generate the best-fit to targets
Proprietary immunization protocols to increase immune responses
High fusion efficiency through electrofusion
High throughput protein-based and cell-based screening platforms that includes five high-throughput flow cytometers and seven Biacore instruments to support screening and affinity ranking
Functional screen using hybridoma supernatants to increase chances of isolating functional leads

Phage Display

WuXi Biologics offers high-quality phage display library construction and customized library selection and screening services via our WuXiLiAb® human naïve / synthetic phage display libraries, VHH naïve / humanized VHH synthetic libraries and antibody immune libraries. In addition, we have extensive experience working with challenging targets such as GPCR (G-Protein Coupled Receptor), ion-channe, and multi-subunit complexes, and small molecule hapten..

Process and Timeline:

WuXi Biologics has constructed human naïve libraries from 50+ donors with more than 1*10¹¹ transformants representing nearly all of the human antibody V-gene repertoire. WuXi Biologics has also designed and constructed human synthetic libraries based on dominant germline pairs of heavy and light chains with more than 1*10¹² transformants. WuXi Biologics has successfully delivered 40+ antibody discovery projects based on human naïve / synthetic display platform. Typical project timelines include:

Naïve / synthetic library panning/screening: 2-3 months
Immune library construction and screening: 3-4 months

Key Features:

In-house ready to use human naïve or synthetic libraries
Immune (custom) libraries: human, mouse, rat, camelid, and common light chain
Liquid-phase, solid-phase and cell-based panning
Epitope guided and Avi-tag captured selections – enable isolation of functionally active antibodies

VHH Generation

WuXi Biologics offers high-quality camelid immune library construction and customized library selection and screening services. WuXi Biologics has constructed camelid naïve libraries from 100+ donors with more than 3*10¹¹ transformants. We have successfully delivered 70+ VHH antibody discovery projects based on immunization and naïve phage display libraries. Typical project timelines include:

Naïve library panning/screening: 2-3 months
Immune library construction and screening: 3-4 months

Key Features:

Liquid-phase, solid-phase and cell-based panning
In-house ready to use alpaca naïve libraries and humanized VHH synthetic libraries
Multiple immunization strategies (DNA, peptide, protein, cell or combinations thereof) to generate the best-fit to targets
Proprietary immunization protocols to increase immune responses
Proprietary primer sets to achieve increased coverage of the camelid VHH gene repertoire

Single B Cell Screening

WuXi Biologics utilizes the Berkeley Lights Beacon Optofluidic^® systems’ highly efficient single B cell screening methodology to identify lead monoclonal antibodies and to dramatically reduce the traditional discovery timelines.

Key Features of Single B Screen on the Beacon® Optofluidic system:

Fast screening. More than 10,000 primary B cells can be analyzed in one day
Multiple cell-based assays can be used for primary screening
Obtain antibody sequences within 2 months
High sequence recovery rate: >90% recombinant antibodies retain antigen binding at initial screening
Mouse, rat, rabbit and camelid antibody discovery capabilities

Typical Single B cell Screening Timeline

Single B Cell Screening Process